Latest Breaking News On - Biocryst pharmaceuticals stock performance - Page 2 : vimarsana.com

BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results, Beats Expectations By $0 06 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results, Beats Expectations By $0 06 EPS
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Biocryst pharmaceuticalsBiocryst pharmaceuticals incNeedham companyBiocryst pharmaceuticals stock performanceEarnings history for biocryst pharmaceuticalsBiocryst pharmaceuticals company profileNews ratings for biocryst pharmaceuticals dailyGet free reportCryst pharmaceuticalsBiocryst pharmaceuticals daily

MA Private Wealth Acquires Shares of 12,700 BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX)

MA Private Wealth Acquires Shares of 12,700 BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Needham companyBiocryst pharmaceuticalsBiocryst pharmaceuticals stock performanceVanguard group incQuarter for biocryst pharmaceuticalsDeerfield management companylp seriesExchange commissionNews ratings for biocryst pharmaceuticals dailyBiocryst pharmaceuticals incJump financialFree reportCapital managementCryst pharmaceuticalsGet free reportVisit holdingschannelBiocryst pharmaceuticals daily

MA Private Wealth Acquires Shares of 12,700 BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX)

MA Private Wealth acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 12,700 shares of the biotechnology company’s stock, valued at approximately $76,000. A number of other hedge funds have also recently bought and sold shares […]

Quarter for biocryst pharmaceuticalsAdvisory services networkFairfield bushThird bancorpLazard asset managementBiocryst pharmaceuticals company profileBiocryst pharmaceuticals incNews ratings for biocryst pharmaceuticals dailyBiocryst pharmaceuticalsNeedham companyBiocryst pharmaceuticals stock performanceFifth third bancorpFree reportAsset managementServices networkCryst pharmaceuticals

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Receives Consensus Rating of Buy from Analysts

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Receives Consensus Rating of Buy from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

News ratings for biocryst pharmaceuticals dailyBiocryst pharmaceuticals incDeerfield management companylp seriesAnalyst recommendations for biocryst pharmaceuticalsRice hall james associatesBiocryst pharmaceuticals company profileBiocryst pharmaceuticals stock performanceHedge funds weigh in on biocryst pharmaceuticalsBiocryst pharmaceuticalsJump financialNeedham companyGet free reportCryst pharmaceuticalsCapital managementRice hall jamesHall james

HC Wainwright Comments on BioCryst Pharmaceuticals, Inc s FY2024 Earnings (NASDAQ:BCRX)

HC Wainwright Comments on BioCryst Pharmaceuticals, Inc s FY2024 Earnings (NASDAQ:BCRX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Biocryst pharmaceuticals company profileFairfield bushNeedham companyJpmorgan chase coBiocryst pharmaceuticals incChina universal asset management coBiocryst pharmaceuticals stock performanceFifth third bancorpThird bancorpInstitutional trading of biocryst pharmaceuticalsBiocryst pharmaceuticalsNews ratings for biocryst pharmaceuticals dailyAdvisory services networkFree reportBiocryst pharmaceuticalCryst pharmaceuticals